None listed
Conditions
Brief summary
The purpose of this study is to conduct a small, translational research trial in a group of men with prostate cancer, to determine the whole-genome effects of lycopene supplementation.
Interventions
Lycopene - oral supplement 3 times daily - 15-90mg for 6-10 weeks; differs on a case-by-case basis as determined by clinician
Sponsors
University of Queensland
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Prevention
Masking
Open (masking not used)
Eligibility
Sex/Gender
Male
Age
35 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
(1) Age 35-80 years (2) Non-smoker (3) Patients with a diagnosis of clinically localised prostate cancer who are scheduled to undergo radical prostatectomy in 6-8 weeks (4) Normal liver function tests, as verification that the tumour is localized to the prostate gland
Exclusion criteria
(1) No diagnosis of prostate cancer (2) Body mass index <18.5kg/m2 (underweight) or >35kg/m2 (obese – class II) (3) Current infection (4) Prior therapy for prostate cancer (e.g. chemotherapy; radiation therapy; hormonal therapy) (5) Current consumption of testosterone replacement medicines (6) Current consumption of 5-alpha-reductase inhibitors (7) Consumption of other herbal or nutritional supplements, apart from a single multi-vitamin tablet (8) Inability to provide informed consent due to diminished understanding or comprehension, or a language other than English spoken and an interpreter unavailable
Outcome results
None listed